Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio, Inc. manages royalty-focused financial collaborations tied to Jemperli with GSK and imsidolimab with Vanda. Following the completed separation of First Tracks Biotherapeutics, the company’s recurring updates center on royalty asset management, collaboration economics, contractual rights, stock repurchase activity, and governance changes.
News about ANAB also includes developments involving imsidolimab, a licensed antibody asset being developed by Vanda, and legal or contractual matters related to the Jemperli collaboration. Company announcements have additionally covered board and finance leadership appointments and the corporate transition from a biopharma operations business to a streamlined royalty management model.
AnaptysBio, a clinical-stage biotechnology company, announced the appointment of Dr. Paul F. Lizzul as Chief Medical Officer on July 31, 2020. Dr. Lizzul brings extensive experience in immune-modulating therapeutics, previously serving at Amgen and Sienna Biopharmaceuticals. AnaptysBio's pipeline includes seven therapeutic antibodies, with ongoing programs like etokimab and imsidolimab aimed at treating inflammatory diseases. The leadership change is expected to enhance the company’s development efforts and support its capital-efficient business model.
AnaptysBio (Nasdaq: ANAB) has appointed Dennis Mulroy as Chief Financial Officer and Eric Loumeau as Chief Operating Officer, enhancing its leadership team. Mulroy, previously CFO at La Jolla Pharmaceutical Company, will oversee finance and investor relations. Loumeau, who has been with AnaptysBio since 2018 and served as Interim CFO, will manage business strategy and operations. These appointments are expected to bolster AnaptysBio's capital-efficient model and advance its pipeline of antibody candidates targeting inflammation and immuno-oncology.
AnaptysBio (Nasdaq: ANAB) announced that the FDA granted orphan drug designation for imsidolimab, an anti-IL-36R antibody targeting generalized pustular psoriasis (GPP), a rare disease affecting approximately 3,000 patients in the U.S. The company anticipates additional data and regulatory updates from the ongoing GALLOP Phase 2 trial for GPP and top-line data from the POPLAR Phase 2 trial for palmoplantar pustulosis (PPP) in H2 2020. AnaptysBio plans to expand imsidolimab's clinical development into additional indications.
AnaptysBio reported Q1 2020 results, revealing a net loss of $8.3 million or $0.30 per share, significantly improved from a net loss of $22.1 million in Q1 2019. Cash reserves totaled $412.7 million, down from $428.5 million. The company anticipates interim data from the ECLIPSE trial in Q3 2020 and has over-enrolled due to COVID-19. Notable developments include the FDA acceptance of the BLA for dostarlimab, earning AnaptysBio significant milestone payments and potential royalties. The firm expects a net cash burn of $60 million for 2020, funding operations through at least 2023.